Corbus Pharma

Corbus Pharma Corbus (Nasdaq: CRBP) is connecting innovation to purpose to improve the futures of cancer and obesity patients.

Recently reported data from Corbus' Phase 1a study showed that CRB-913-treated participants in the MAD cohort of people ...
12/15/2025

Recently reported data from Corbus' Phase 1a study showed that CRB-913-treated participants in the MAD cohort of people with obesity experienced weight loss which started early and deepened with time, achieving a mean placebo-adjusted weight loss of 2.9% by Day 14.

Stat News details results from our Phase 1a study of CRB-913 for the treatment of obesity which showed CRB-913 was safe...
12/12/2025

Stat News details results from our Phase 1a study of CRB-913 for the treatment of obesity which showed CRB-913 was safe and well-tolerated across all doses studied. A 12-week dose-finding study in people with obesity has been initiated with completion expected in summer 2026.

And more biotech news updates brought to you by The Readout

12/11/2025

"We are pleased by the translation of CRB-913 from pre-clinical models to the clinical setting." -Yuval Cohen, PhD, Chief Executive Officer of Corbus comments on results from the Phase 1a study of CRB-913 for the treatment for obesity. Learn more about the results here: https://bit.ly/4q7X8Rk

12/11/2025

In the dedicated MAD cohort of people with obesity, all CRB-913-treated participants, and none in the placebo group, experienced weight loss. The CRB-913-treated participants achieved a mean 2.9% placebo-adjusted weight loss by Day 14. For more info: https://bit.ly/4q7X8Rk

12/11/2025

Corbus today announced the completion of the single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a study of CRB-913 and the initiation of a Phase 1b dose-range finding study ("CANYON-1"), with completion expected in summer 2026. CRB-913 was safe and well-tolerated across all doses studied and daily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participants. Learn more here: https://bit.ly/4q7X8Rk

12/10/2025

Corbus will host a conference call and live webcast tomorrow at 8:00 am ET to review and discuss the results of its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of CRB-913. For webcast details, visit: https://bit.ly/4iSlw6P

12/02/2025

Reminder: Corbus CEO Yuval Cohen, Ph.D. will present at Evercore’s 8th Annual Healthcare Conference in Miami today, December 2nd at 3:50 p.m. ET. Watch the webcast here: https://bit.ly/4ozONVX

11/25/2025

Yuval Cohen, Ph.D., Corbus CEO, will present at Evercore’s 8th Annual Healthcare Conference in Miami on Tuesday, December 2nd at 3:50 p.m. ET. For webcast details: https://bit.ly/4ozONVX

11/18/2025

Tune-in today, November 18th at 4 p.m. GMT for Corbus CEO Yuval Cohen's presentation at the Jefferies Global Healthcare Conference in London. Watch the webcast here: https://bit.ly/4rbDuoT

11/14/2025

Corbus CEO Yuval Cohen, Ph.D. will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18th at 4 p.m. GMT. Register for the webcast here: https://bit.ly/4rbDuoT

11/12/2025

“This has been a productive period for Corbus, led by the presentation of CRB-701 data at ESMO 2025,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. For key corporate and program updates, visit: https://bit.ly/4oBDZql

11/12/2025

Corbus today provided a corporate update and reported financial results for the quarter ended September 30, 2025. For details: https://bit.ly/4oBDZql

Address

500 River Ridge Drive, Second Floor
Norwood, MA
02062

Opening Hours

Monday 8:30am - 5:30pm
Tuesday 8:30am - 5:30pm
Wednesday 8:30am - 5:30pm
Thursday 8:30am - 5:30pm
Friday 9am - 5:30pm

Telephone

+16179630100

Website

Alerts

Be the first to know and let us send you an email when Corbus Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Corbus Pharma:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates. The Company's lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

Corbus licensed the exclusive worldwide rights to develop, manufacture and market drug candidates from more than 600 novel compounds targeting the endocannabinoid system from Jenrin Discovery LLC. The pipeline includes CRB-4001, a 2nd generation, peripherally-restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist specifically designed to eliminate blood-brain barrier pe*******on and brain CB1 receptor occupancy that mediate the neuropsychiatric issues associated with first-generation CB1 inverse agonists. Potential indications for CRB-4001 include NASH, primary biliary cholangitis, idiopathic pulmonary fibrosis, radiation-induced pulmonary fibrosis, myocardial fibrosis after myocardial infarction and acute interstitial nephritis, among others. CRB-4001 is scheduled to enter a Phase 1 study in 2019 followed a National Institutes of Health (NIH)-funded first-in-patient Phase 2 study.